Capital Fund Management (CFM)
NBIX icon

Capital Fund Management (CFM)’s Neurocrine Biosciences NBIX Stock Holding History

Capital Fund Management (CFM)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,100
Closed -$1.29M – 1957
2018
Q4 		$1.29M Sell
18,100
-20,900
-54% -$2M 0.01% 1016
2018
Q3 		$4.79M Buy
+39,000
New +$4.42M 0.03% 782
2018
Q2 		– Sell
-78,200
Closed -$6.49M – 2188
2018
Q1 		$6.49M Buy
+78,200
New +$6.6M 0.04% 590

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s NBIX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, selling an estimated $7.64M and leaving 98,117 shares worth $16.5M. The position accounts for 0.07% of the portfolio, ranked #389.

Capital Fund Management (CFM) first reported a position in NBIX in Q2 2015 and has held it in 26 quarters since. The position peaked at $25.6M in Q2 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Capital Fund Management (CFM) held 98,117 shares of Neurocrine Biosciences worth $16.5M as of Q2 2026.
  • Capital Fund Management (CFM) sold 51,514 Neurocrine Biosciences shares in Q2 2026, an estimated $7.64M.
  • Neurocrine Biosciences made up 0.07% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #389 holding.
  • Capital Fund Management (CFM) first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 26 quarters since.
  • Capital Fund Management (CFM)'s Neurocrine Biosciences position peaked at $25.6M in Q2 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.